TPBG and neoplasm: These novel constructs were found to have more potent anti-tumor activity than parental monospecific or T-cell engager bi-specific mAbs, since they combine the T-cell recruiting ability of the parental bi-specific anti-5T4/CD3 with the immunomodulatory function of the anti-IC antibodies [30].